Overview of Bio-Gene Technology Ltd's Investor Webinar

Bio-Gene Technology Limited (ASX: $BGT) will hold an investor webinar today, Tuesday, 5 March 2024, at 11:00am (AEDT) to present the 1H FY24 results. The webinar, hosted by Chief Executive Officer, Tim Grogan, will cover key milestones achieved and partnerships in the development of novel insecticides.

Executive Commentary on FY24 Half Year Report

The FY24 Half Year Report reflects significant progress in Bio-Gene's development pipeline, particularly in public health, consumer, and crop protection. The company has accelerated the development of Qcide Al and secured a US$10 million research program funded by the US Centers for Disease Control and Prevention for vector control targeting ticks as vectors of Lyme disease. Additionally, key board and management changes have been made to match the scale-up of Qcide to regulatory developments.

Summary of FY24 Half Year Report and Outlook

Bio-Gene Technology Limited's FY24 Half Year Report highlights the successful scale-up of Qcide production and the development of Flavocide. The company has secured significant partnerships with Clarke Mosquito Control Products, Inc., Evergreen Garden Care, and STK Bio-Ag Technologies, positioning itself for commercial success in the insecticide market. Looking ahead, Bio-Gene aims to achieve regulatory filings for Flavocide AI and Qcide AI by December 2025, while also focusing on expanding partnerships and sustaining value creation in the medium and long term. The company's strategic priorities include speed, focused product development, commercial validation, efficient use of capital, and developing biological products with critical success factors. With a strong board and management team, Bio-Gene is well-positioned to continue its growth and innovation in the agtech sector.